AAPL324.53-0.61 (-0.19%) ▼|ABBV258.72-1.27 (-0.49%) ▼|ABT112.09+3.16 (+2.90%) ▲|ACN186.16-1.93 (-1.03%) ▼|ADBE282.68-3.41 (-1.19%) ▼|AMAT437.13-4.73 (-1.07%) ▼|AMD457.95-1.66 (-0.36%) ▼|AMGN437.01-1.11 (-0.25%) ▼|AMT174.30-1.72 (-0.98%) ▼|AMZN255.10+0.18 (+0.07%) ▲|AVGO369.77+0.09 (+0.02%) ▲|AXP329.95+5.76 (+1.78%) ▲|BA210.00+4.34 (+2.11%) ▲|BAC63.18+1.19 (+1.91%) ▲|BKNG198.67+2.98 (+1.52%) ▲|BLK1,123.43-4.67 (-0.41%) ▼|BMY67.06+0.14 (+0.21%) ▲|BNY161.84+1.33 (+0.83%) ▲|BRK-B507.73+5.40 (+1.08%) ▲|C134.93+2.39 (+1.80%) ▲|CAT785.34+6.18 (+0.79%) ▲|CL90.45+0.82 (+0.91%) ▲|CMCSA27.06+0.76 (+2.89%) ▲|COF218.64+7.30 (+3.45%) ▲|COP136.28+0.09 (+0.07%) ▲|COST934.82-5.14 (-0.55%) ▼|CRM255.33-2.79 (-1.08%) ▼|CSCO109.01-0.73 (-0.67%) ▼|CVS98.41+0.81 (+0.83%) ▲|CVX211.71+0.66 (+0.31%) ▲|DE686.10+10.02 (+1.48%) ▲|DHR210.09+3.16 (+1.52%) ▲|DIS108.68+2.46 (+2.31%) ▲|DUK120.34-0.05 (-0.04%) ▼|EMR149.61+1.98 (+1.34%) ▲|FDX322.30-2.58 (-0.79%) ▼|GD363.41-6.01 (-1.63%) ▼|GE332.17+1.08 (+0.33%) ▲|GEV901.08+2.55 (+0.28%) ▲|GILD150.10+0.18 (+0.12%) ▲|GM85.09-0.54 (-0.63%) ▼|GOOG333.66+1.63 (+0.49%) ▲|GOOGL337.29+2.27 (+0.68%) ▲|GS1,007.58+5.02 (+0.50%) ▲|HD320.31+0.54 (+0.17%) ▲|HON208.39-1.59 (-0.76%) ▼|IBM230.57-0.83 (-0.36%) ▼|INTC89.54+0.57 (+0.64%) ▲|INTU343.17-1.77 (-0.51%) ▼|ISRG380.16+10.91 (+2.95%) ▲|JNJ274.41+3.22 (+1.19%) ▲|JPM358.82+3.87 (+1.09%) ▲|KO88.78+0.78 (+0.89%) ▲|LIN488.69+1.93 (+0.40%) ▲|LLY1,174.01+14.01 (+1.21%) ▲|LMT533.01-11.50 (-2.11%) ▼|LOW201.48+1.43 (+0.71%) ▲|LRCX287.10-3.10 (-1.07%) ▼|MA589.42+8.32 (+1.43%) ▲|MCD262.52+1.41 (+0.54%) ▲|MDLZ62.37+0.76 (+1.23%) ▲|MDT94.26+2.22 (+2.41%) ▲|META595.84+17.30 (+2.99%) ▲|MMM169.96-0.28 (-0.17%) ▼|MO69.49-0.08 (-0.12%) ▼|MRK150.63+0.77 (+0.51%) ▲|MS213.63+2.59 (+1.23%) ▲|MSFT497.62-3.40 (-0.68%) ▼|MU940.77+7.33 (+0.78%) ▲|NEE82.77-0.16 (-0.19%) ▼|NFLX82.68+1.87 (+2.31%) ▲|NKE38.48+0.36 (+0.94%) ▲|NOW138.12-4.78 (-3.35%) ▼|NVDA226.23+8.79 (+4.04%) ▲|ORCL145.44+4.12 (+2.92%) ▲|PEP141.48+1.69 (+1.21%) ▲|PFE28.86+0.31 (+1.07%) ▲|PG147.58+1.37 (+0.94%) ▲|PLTR170.04-9.88 (-5.49%) ▼|PM188.16+1.01 (+0.54%) ▲|QCOM169.42+2.81 (+1.69%) ▲|RTX202.29-2.87 (-1.40%) ▼|SBUX107.60+1.45 (+1.37%) ▲|SCHW109.43+1.15 (+1.06%) ▲|SO88.02-0.07 (-0.08%) ▼|SPG210.21-1.66 (-0.78%) ▼|T26.36+0.36 (+1.37%) ▲|TMO607.30+6.80 (+1.13%) ▲|TMUS187.48+5.32 (+2.92%) ▲|TSLA355.30-0.79 (-0.22%) ▼|TXN256.70+3.36 (+1.32%) ▲|UBER76.60+1.36 (+1.80%) ▲|UNH400.09+3.79 (+0.96%) ▲|UNP290.67+0.05 (+0.02%) ▲|UPS103.26+0.60 (+0.58%) ▲|USB62.60+1.39 (+2.26%) ▲|V379.26+6.59 (+1.77%) ▲|VZ50.69+0.39 (+0.77%) ▲|WFC89.67+2.63 (+3.02%) ▲|WMT106.05+0.13 (+0.12%) ▲|XOM163.07-1.49 (-0.90%) ▼|AAPL324.53-0.61 (-0.19%) ▼|ABBV258.72-1.27 (-0.49%) ▼|ABT112.09+3.16 (+2.90%) ▲|ACN186.16-1.93 (-1.03%) ▼|ADBE282.68-3.41 (-1.19%) ▼|AMAT437.13-4.73 (-1.07%) ▼|AMD457.95-1.66 (-0.36%) ▼|AMGN437.01-1.11 (-0.25%) ▼|AMT174.30-1.72 (-0.98%) ▼|AMZN255.10+0.18 (+0.07%) ▲|AVGO369.77+0.09 (+0.02%) ▲|AXP329.95+5.76 (+1.78%) ▲|BA210.00+4.34 (+2.11%) ▲|BAC63.18+1.19 (+1.91%) ▲|BKNG198.67+2.98 (+1.52%) ▲|BLK1,123.43-4.67 (-0.41%) ▼|BMY67.06+0.14 (+0.21%) ▲|BNY161.84+1.33 (+0.83%) ▲|BRK-B507.73+5.40 (+1.08%) ▲|C134.93+2.39 (+1.80%) ▲|CAT785.34+6.18 (+0.79%) ▲|CL90.45+0.82 (+0.91%) ▲|CMCSA27.06+0.76 (+2.89%) ▲|COF218.64+7.30 (+3.45%) ▲|COP136.28+0.09 (+0.07%) ▲|COST934.82-5.14 (-0.55%) ▼|CRM255.33-2.79 (-1.08%) ▼|CSCO109.01-0.73 (-0.67%) ▼|CVS98.41+0.81 (+0.83%) ▲|CVX211.71+0.66 (+0.31%) ▲|DE686.10+10.02 (+1.48%) ▲|DHR210.09+3.16 (+1.52%) ▲|DIS108.68+2.46 (+2.31%) ▲|DUK120.34-0.05 (-0.04%) ▼|EMR149.61+1.98 (+1.34%) ▲|FDX322.30-2.58 (-0.79%) ▼|GD363.41-6.01 (-1.63%) ▼|GE332.17+1.08 (+0.33%) ▲|GEV901.08+2.55 (+0.28%) ▲|GILD150.10+0.18 (+0.12%) ▲|GM85.09-0.54 (-0.63%) ▼|GOOG333.66+1.63 (+0.49%) ▲|GOOGL337.29+2.27 (+0.68%) ▲|GS1,007.58+5.02 (+0.50%) ▲|HD320.31+0.54 (+0.17%) ▲|HON208.39-1.59 (-0.76%) ▼|IBM230.57-0.83 (-0.36%) ▼|INTC89.54+0.57 (+0.64%) ▲|INTU343.17-1.77 (-0.51%) ▼|ISRG380.16+10.91 (+2.95%) ▲|JNJ274.41+3.22 (+1.19%) ▲|JPM358.82+3.87 (+1.09%) ▲|KO88.78+0.78 (+0.89%) ▲|LIN488.69+1.93 (+0.40%) ▲|LLY1,174.01+14.01 (+1.21%) ▲|LMT533.01-11.50 (-2.11%) ▼|LOW201.48+1.43 (+0.71%) ▲|LRCX287.10-3.10 (-1.07%) ▼|MA589.42+8.32 (+1.43%) ▲|MCD262.52+1.41 (+0.54%) ▲|MDLZ62.37+0.76 (+1.23%) ▲|MDT94.26+2.22 (+2.41%) ▲|META595.84+17.30 (+2.99%) ▲|MMM169.96-0.28 (-0.17%) ▼|MO69.49-0.08 (-0.12%) ▼|MRK150.63+0.77 (+0.51%) ▲|MS213.63+2.59 (+1.23%) ▲|MSFT497.62-3.40 (-0.68%) ▼|MU940.77+7.33 (+0.78%) ▲|NEE82.77-0.16 (-0.19%) ▼|NFLX82.68+1.87 (+2.31%) ▲|NKE38.48+0.36 (+0.94%) ▲|NOW138.12-4.78 (-3.35%) ▼|NVDA226.23+8.79 (+4.04%) ▲|ORCL145.44+4.12 (+2.92%) ▲|PEP141.48+1.69 (+1.21%) ▲|PFE28.86+0.31 (+1.07%) ▲|PG147.58+1.37 (+0.94%) ▲|PLTR170.04-9.88 (-5.49%) ▼|PM188.16+1.01 (+0.54%) ▲|QCOM169.42+2.81 (+1.69%) ▲|RTX202.29-2.87 (-1.40%) ▼|SBUX107.60+1.45 (+1.37%) ▲|SCHW109.43+1.15 (+1.06%) ▲|SO88.02-0.07 (-0.08%) ▼|SPG210.21-1.66 (-0.78%) ▼|T26.36+0.36 (+1.37%) ▲|TMO607.30+6.80 (+1.13%) ▲|TMUS187.48+5.32 (+2.92%) ▲|TSLA355.30-0.79 (-0.22%) ▼|TXN256.70+3.36 (+1.32%) ▲|UBER76.60+1.36 (+1.80%) ▲|UNH400.09+3.79 (+0.96%) ▲|UNP290.67+0.05 (+0.02%) ▲|UPS103.26+0.60 (+0.58%) ▲|USB62.60+1.39 (+2.26%) ▲|V379.26+6.59 (+1.77%) ▲|VZ50.69+0.39 (+0.77%) ▲|WFC89.67+2.63 (+3.02%) ▲|WMT106.05+0.13 (+0.12%) ▲|XOM163.07-1.49 (-0.90%) ▼|
21.3 C
New York
Wednesday, September 2, 2026

Tag: medicine

newssourceFORcompanyinformationcontent1releasesmarket

LIfT BioSciences announces grant of €12 million from Ireland’s Disruptive Technologies Innovation Fund to support the first-in-human clinical trial of LIfT’s IMAN therapy

Basilea initiates phase 3 study with antifungal fosmanogepix in invasive mold infections

Allschwil, Switzerland, July 29, 2025

FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria. C3G and primary IC-MPGN are rare kidney diseases, affecting 5,000 people in the United States.1

Vaccines: Mythology, Ideology, and Reality, New Book by John Leake and Peter A. McCullough

NEW YORK, July 28, 2025 /PRNewswire/ -- Vaccines: Mythology, Ideology, and Reality tells the story of immunizations and the celebrated men who developed it with...

Biologic Therapeutics Market to Hit $794.5 Billion by 2029

"Driven by Rising Chronic Disease Burden and Breakthrough FDA Approvals, Biopharmaceutical Market Surges with Demand for Monoclonal Antibodies, Gene and Cell Therapies, and Innovative...

Biologic Therapeutics Market to Hit $794.5 Billion by 2029

"Driven by Rising Chronic Disease Burden and Breakthrough FDA Approvals, Biopharmaceutical Market Surges with Demand for Monoclonal Antibodies, Gene and Cell Therapies, and Innovative...

ROSEN, A LEADING LAW FIRM, Encourages 3D Systems Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – DDD

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of 3D Systems Corporation (NYSE: DDD) between August 13, 2024 and May 12, 2025, both dates inclusive (the “Class Period”), of the important August 12, 2025 lead plaintiff deadline.

The Pink Salt Trick Recipe for Fast Weight Loss Trend in 2025: Why ProZenith Is the Science-Backed Alternative

Why the TikTok Pink Salt Trick Went Viral in 2025 —and How ProZenith Offers a Science‑Based Solution for Hormonal Metabolic Support 
Why the TikTok Pink Salt Trick Went Viral in 2025 —and How ProZenith Offers a Science‑Based Solution for Hormonal Metabolic Support

iCRYO Adds Dr. Jason Sonners to Medical Advisory Board, Strengthens Commitment to Safe, Effective Hyperbaric Oxygen Therapy

HOUSTON, July 28, 2025 /PRNewswire/ -- iCRYO, a leading health, wellness, and longevity franchise, is proud to announce the appointment of Dr. Jason Sonners,...

Warburg Pincus and Carlyle Announce Agreement to Sell NEOGOV to EQT and CPP Investments

Sale reflects NEOGOV's industry-leading position in purpose-built government HR and compliance software solutions, providing an essential service to public-sector agencies NEW YORK, July 28, 2025...

Elevate Holistics Launches Comprehensive Cannabis E-Book After Years of Consulting Patients on the Most Important Questions When It Comes to Cannabis

MORGANTOWN, W.Va., July 28, 2025 /PRNewswire/ -- "Everything You've Ever Wanted to Know About Cannabis, Finally Written Down" ...

BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants.

July 28, 2025
News Release

Roche presents new insights in Alzheimer’s disease research across its diagnostics and pharmaceutical portfolios at AAIC

Basel, 28 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer’s development portfolio is being presented at the Alzheimer’s Association International Conference (AAIC) in Toronto, Canada (July 27-30). These data exemplify the comprehensive approach Roche is taking in addressing Alzheimer’s across the entire patient journey. 

NurExone Biologic Finalist in Falling Walls Venture 2025 Global Platform Showcasing The World’s Most Promising Science-Based Start-Ups

Company to compete for “Science Breakthrough of the Year” at Europe’s leading deep-tech summit in Berlin, Germany this November 
Company to compete for “Science Breakthrough of the Year” at Europe’s leading deep-tech summit in Berlin, Germany this November

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMedicine

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers